JonesResearch downgraded Adaptimmune Therapeutics (ADAP) to Hold from Buy and suspended the firm’s price target on the shares after Adaptimmune and TCR2 Therapeutics (TCRR) announced an agreement under which Adaptimmune will combine with TCR in an all-stock transaction. Adaptimmune shareholders will own approximately 75% of the combined company based on the terms of the deal, noted the firm, which thinks the synergy and value creation from the merger is "unclear."
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ADAP:
- Adaptimmune Craters after Acquiring TCRR
- Adaptimmune, TCR2 Therapeutics to combine in all-stock transaction
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue